20201006 Transgene_NEC_BostonGene_Press_Release_final
Category: Myvac
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
20200709 PR Hypertrust Transgene EN
Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
20200515_AACR myvac curtain raiser EN
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
20190916 PR ANSM TG4050 EN
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
20190710 PR MHRA TG4050 EN
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
